摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[6-(3,5-Dimethyl-pyrazol-1-yl)-2-pyridin-2-yl-pyrimidin-4-yl]-2-(4-methyl-piperazin-1-yl)-acetamide | 912939-95-8

中文名称
——
中文别名
——
英文名称
N-[6-(3,5-Dimethyl-pyrazol-1-yl)-2-pyridin-2-yl-pyrimidin-4-yl]-2-(4-methyl-piperazin-1-yl)-acetamide
英文别名
[6-(3,5-Dimethyl-pyrazol-1-yl)-2-pyridin-2-yl-pyrimidin-4-yl]-2-(4-methyl-piperazin-1-yl)-acetamide;N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]-2-(4-methylpiperazin-1-yl)acetamide;N-[6-(3,5-dimethylpyrazol-1-yl)-2-pyridin-2-ylpyrimidin-4-yl]-2-(4-methylpiperazin-1-yl)acetamide
N-[6-(3,5-Dimethyl-pyrazol-1-yl)-2-pyridin-2-yl-pyrimidin-4-yl]-2-(4-methyl-piperazin-1-yl)-acetamide化学式
CAS
912939-95-8
化学式
C21H26N8O
mdl
——
分子量
406.49
InChiKey
IWFABDHEBLKWSW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    92.1
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    N-甲基哌嗪 、 2-chloro-N-[6-(3,5-dimethylpyrazol-1-yl)-2-pyridin-2-ylpyrimidin-4-yl]acetamide 在 N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 生成 N-[6-(3,5-Dimethyl-pyrazol-1-yl)-2-pyridin-2-yl-pyrimidin-4-yl]-2-(4-methyl-piperazin-1-yl)-acetamide
    参考文献:
    名称:
    2-Amino-N-pyrimidin-4-ylacetamides as A2A Receptor Antagonists: 1. Structure−Activity Relationships and Optimization of Heterocyclic Substituents
    摘要:
    Previously we have described a novel series of potent and selective A(2A) receptor antagonists (e.g., 1) with excellent aqueous solubility.(1) While these compounds are efficacious A(2A) antagonists in vivo, the presence of an unsubstituted furyl moiety was a cause of some concern. In order to avoid the potential metabolic liabilities that could arise from an unsubstituted fury] moiety, an optimization effort was undertaken with the aim of replacing the unsubstituted furan with a more metabolically stable group while maintaining potency and selectivity. Herein, we describe the synthesis and SAR of a range of novel heterocyclic systems and the successful identification of a replacement for the unsubstituted furan moiety with a methylfuran or thiazole moiety while maintaining potency and selectivity.
    DOI:
    10.1021/jm701185v
点击查看最新优质反应信息

文献信息

  • Substituted Pyrimidines as Adenosine Receptor Antagonists
    申请人:Slee Deborah
    公开号:US20080275064A1
    公开(公告)日:2008-11-06
    Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.
    式(I)的化合物,包括药学上可接受的盐、酯、溶剂合物和立体异构体,其中R1、R2和R3的定义如本文所述。含有式(I)化合物的制药组合物,以及与其使用作为腺苷受体拮抗剂相关的方法,特别是A2A腺苷受体亚型的拮抗剂。
  • 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
    申请人:Almirall, S.A.
    公开号:EP1888565B1
    公开(公告)日:2011-03-23
  • [EN] SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] PYRIMIDINES SUBSTITUEES UTILISEES COMME ANTAGONISTES DU RECEPTEUR D'ADENOSINE
    申请人:NEUROCRINE BIOSCIENCES INC
    公开号:WO2006110884A2
    公开(公告)日:2006-10-19
    (EN) Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, Rl, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.(FR) Cette invention concerne des composés représentés par la formule (I), y compris des sels, esters, solvates, stéréo-isomères et promédicaments de ceux-ci, R1, R2 and R3 étant définis dans la demande. Des compositions pharmaceutiques contenant un composé de structure (I) ainsi que des procédés relatifs à l'utilisation de ces compositions sont également décrits.
查看更多